Monograph Details
|
|
Neoplasms
> Cytoprotective agents
|
|
Leucovorin |
| Manufacturer |
|
Teva Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Folic acid derivative. |
| Generic Name |
|
Leucovorin calcium 100mg/vial, 350mg/vial; lyophilized pwd for IV or IM inj after reconstitution; preservative-free. |
| Indications |
|
Rescue treatment after high-dose methotrexate therapy in osteosarcoma. |
| Children |
|
See literature. |
| Adults |
|
Max IV infusion rate: 160mg/min. Based on methotrexate dose. Normal methotrexate elimination: 15mg IM or IV every 6 hours for 10 doses starting 24 hours after the beginning of the methotrexate infusion. Delayed late or delayed early methotrexate elimination, and/or evidence of acute renal injury, impaired methotrexate elimination or inadvertent overdosage: see literature. |
| Contraindications |
|
Pernicious anemia and other megaloblastic anemias due to Vit. B12 deficiency. |
| Precautions |
|
Do not administer intrathecally. Monitor serum methotrexate concentration. CNS metastases. Monitor CBCs with differential, platelets, electrolytes, liver function tests prior to each treatment, then periodically. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Potentiates toxicity of 5-fluorouracil; use lower 5-fluorouracil dose. May antagonize phenobarbital, phenytoin, and primidone. Caution with trimethoprim-sulfamethoxazole. |
| Adverse Reactions |
|
Leukopenia, thrombocytopenia, infection, GI upset, stomatitis, constipation, lethargy, malaise, fatigue, alopecia, dermatitis, anorexia; seizures, syncope. |
| How Supplied |
|
Single-use vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
